Prognostic significance of the modified Glasgow Prognostic Score in NSCLC patients undergoing immune checkpoint inhibitor therapy: a meta-analysis DOI Creative Commons
Jiaxuan Wu, Haoyu Wang,

Ruiyuan Yang

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Oct. 11, 2024

Background The modified Glasgow Prognosis Score (mGPS), which considers both inflammatory response and nutritional status, has been linked to the prognosis of various tumors. relationship between mGPS non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs) is still a subject debate. This meta-analysis aims comprehensively assess association survival in NSCLC treated with ICIs. Methods A thorough review studies from PubMed, Web Science, Scopus, Embase was conducted up June 4, 2024. Fixed-effect or random-effect models were employed, combining hazard ratios (HRs) 95% confidence intervals (CI), prognostic value for OS PFS immunotherapy. Results total 1,022 11 recruited. Combined results showed that elevation significantly associated poor (HR = 1.63, 95%CI: 1.42-1.87, P < 0.01) 1.71, 1.31-2.24, 0.01). Subgroup analysis sensitivity further determined predictive effect elevated on deterioration Conclusion can be used as good noninvasive biomarker demonstrate clinical significance undergoing Systematic registration http://www.crd.york.ac.uk/prospero/ PROSPERO, identifier CRD42023432661.

Language: Английский

Baseline (modified) Glasgow prognostic score as a predictor of therapeutic response to immune checkpoint inhibitors in solid tumors: A systematic review and meta‑analysis DOI Open Access
Hong Ye, Meifang Li

Oncology Letters, Journal Year: 2025, Volume and Issue: 29(4)

Published: Feb. 13, 2025

A systemic analysis was performed to evaluate the prognostic utility of Glasgow score (GPS) and modified (m)GPS in cancer patients treated with immune checkpoint inhibitors (ICI). The PubMed, Cochrane Library, EMBASE Google Scholar databases were searched for entries added until May 1st, 2023, obtain relevant articles this study. examined several clinical outcomes, including overall survival (OS), progression‑free (PFS), objective response rate disease control (DCR). In analysis, a total 38 3,772 included. pooled results indicated that high GPS levels had shorter OS [GPS 2 vs. 0, hazard ratio (HR): 4.35, P<0.001; 1 HR: 2.00, 1/0, 2.62, 2/1 2.60, P<0.001) PFS (GPS 2.11, P=0.001; 1.33, 1.62, P<0.001], as well lower DCR odds (OR): 0.53, P<0.001, OR: 0.51, P<0.001]. It also found mGPS poorer (mGPS 3.15, 1.70, 1.95, P=0.049; 3.14, P=0.041; continuous variables, 1.52, 2.70, 1.74, P=0.016; 1.91, P=0.044; 1.29, P<0.001), 0.46, P<0.001). conclusion, reliable predictors outcomes ICIs.

Language: Английский

Citations

0
Prognostic significance of the modified Glasgow Prognostic Score in NSCLC patients undergoing immune checkpoint inhibitor therapy: a meta-analysis DOI Creative Commons
Jiaxuan Wu, Haoyu Wang,

Ruiyuan Yang

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Oct. 11, 2024

Background The modified Glasgow Prognosis Score (mGPS), which considers both inflammatory response and nutritional status, has been linked to the prognosis of various tumors. relationship between mGPS non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs) is still a subject debate. This meta-analysis aims comprehensively assess association survival in NSCLC treated with ICIs. Methods A thorough review studies from PubMed, Web Science, Scopus, Embase was conducted up June 4, 2024. Fixed-effect or random-effect models were employed, combining hazard ratios (HRs) 95% confidence intervals (CI), prognostic value for OS PFS immunotherapy. Results total 1,022 11 recruited. Combined results showed that elevation significantly associated poor (HR = 1.63, 95%CI: 1.42-1.87, P &lt; 0.01) 1.71, 1.31-2.24, 0.01). Subgroup analysis sensitivity further determined predictive effect elevated on deterioration Conclusion can be used as good noninvasive biomarker demonstrate clinical significance undergoing Systematic registration http://www.crd.york.ac.uk/prospero/ PROSPERO, identifier CRD42023432661.

Language: Английский

Citations

1